Treatment of systemic lupus erythematosus with bromocriptine

Lupus

Volumn 10, Issue 3, 2001, Pages 197-202

  Walker, S E ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Bromocriptine; Prolactin; Systemic lupus erythematosus

Indexed keywords

BROMOCRIPTINE; CYTOKINE; HYDROXYCHLOROQUINE; PROLACTIN;

AUTOIMMUNITY; CONTROLLED STUDY; DISEASE ACTIVITY; FEMALE; LIFESPAN; MOUSE; NONHUMAN; PRIORITY JOURNAL; RELAPSE; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; BROMOCRIPTINE; HORMONE ANTAGONISTS; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC;

EID: 0035047508     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/096120301666625458     Document Type: Review

References (44)

1. Prolactin secretion and its control
2. Molecular actions of prolactin in the immune system
3. Prolactin induction of interleukin-2 on rat splenic lymphocytes
4. Effects of prolactin in stimulating disease activity in systemic lupus erythematosus
5. Immunoregulatory properties of growth hormone and prolactin
6. Structural symmetry of the extracellular domain of the cytokine/growth hormone/prolactin receptor family and interferon receptors revealed by hydrophobic cluster analysis
7. Pituitary hormones regulate c-myc and DNA synthesis in lymphoid tissue
8. Potentiation of antibody responsiveness after the transplantation of a syngeneic pituitary gland
9. Cysteamine produces dose-related bidirectional immunomodulatory effects in mice
10. Animal models of systemic lupus erythematosus
11. Sex hormone modulation of autoimmunity in NZB/NZW mice
12. Premature death with bladder outlet obstruction and hyperprolactinemia in New Zealand Black×New Zealand White mice treated with ethinyl estradiol and 17 beta-estradiol
13. Prolactin influences autoimmune disease activity in the female B/W mouse
14. Prolactin and autoimmune disease
15. 1 mice: Accelerated autoimmune disease with normal circulating testosterone
16. Bromocriptine has little direct effect on murine lymphocytes, the immunomodulatory effect being mediated by the suppression of prolactin secretion
17. 1 mouse model of systemic lupus erythematosus
18. Clinical, endocrine, roentgenographic, and immune characterization of hyperprolactinemic women
19. Anti-thyroid antibodies in patients with hyperprolactinemia
20. Autoantibody profile in the sera of women with hyperprolactinemia
21. High association between hyperprolactinemia and anticardiolipin antibodies
22. Prolactin levels and antinuclear antibody profiles in women tested for connective tissue disease
23. Roles of prolactin and gonadotropin releasing hormone in rheumatic diseases
24. Hyperprolactinemia in systemic lupus erythematosus
25. Prolactin and gonadal hormones during pregnancy in systemic lupus erythematosus
26. Hyperprolactinemia in systemic lupus erythematosus: Association with disease activity
27. Elevated serum prolactin or elevated prolactin/cortisol ratio are associated with autoimmune processes in systemic lupus erythematosus and other connective tissue diseases
28. Relationship between endocrine, immune and clinical variables in patients with systemic lupus erythematosus
29. Basal and after-stimuli test for prolactinemia in systemic lupus erythematosus
30. Prolatin in systemic lupus erythematosus
31. No correlation between prolactin levels and clinical activity in patients with systemic lupus erythematosus
32. Hyperprolactenimia in systemic lupus erythematosus
33. Prolactin levels in patients with systemic lupus erythematosus: A case controlled study
34. Clinical significance of seruma nd urine prolactin levels in lupus glomerulonephritis
35. Intravenous immunoglobulin and bromocriptine in the treatment of refractory neuropsychiatric systemic lupus erythematosus
36. Londgstanding hyperprolactinemia associated with systemic erythematosus: Possible hormonal stimulation of an autoimmune disease
37. Proalctin modulates the disease activity of systemic lupus erythematosus accompanied by prolactinoma
38. Efficacy of bromocriptine in an open label therapeutic trial for systemic lupus erythematosus
39. Mood states and disease activity in patients with systemic lupus erythematosus treated with bromocriptine
40. Bromocriptine in systemic lupus erythematosus: A double-blind, randomized, placebo-controlled study
41. Treatment of active systemic lupus erythematosus (SLE) with the prolactin (PRL) lowering drug, bromocriptine (BC): Imparison with hydroxychloroquine (HC) in a randomized, blinded one-year study
42. Immune system development and function in prolactin receptor-deficient mice
43. Immunosuppressive activity of bromocriptine on human T lymphocyte function in vitro
44. Immunosuppressive property of bromocriptine on human B lymphocyte function in vitro